

From: [Gildner, Jean](#)  
To: [Janice Castillo \(jcastillo@Portola.com\)](mailto:Janice.Castillo@Portola.com)  
Subject: BI125586 Information Request  
Date: Friday, November 17, 2017 4:39:59 PM  
Attachments: [image001.png](#)

---

Dear Janice,

Please see the following information request. Please respond on or before November 28. If you are not able to meet this deadline please let me know. Please acknowledge receipt of this email.

***In your August 03, 2017 response to question 2bi in our August 17, 2016 Complete Response Letter, you stated that “a newly implemented (b) (4) assay was established for the (b) (4) (Section 3.2.S.4.3.1.11).” However, based on the submitted information, this assay is used to assess (b) (4), not the (b) (4). Please include (b) (4) as a parameter in the (b) (4) specifications with a reference to a validated method, as the Agency had requested previously.***

Sincerely, Jean

*Jean F. Gildner* MSHS, MT (ASCP)

**Regulatory Project Manager**  
**Center for Biologics Evaluation and Research**  
**Office of Tissues and Advanced Therapies**  
**U.S. Food and Drug Administration**  
Tel: 240-402-8296  
[jean.gildner@fda.hhs.gov](mailto:jean.gildner@fda.hhs.gov)



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.